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Abstract
Background: Small molecule antagonists of mosquito dopamine receptors (DARs) are under investigation as a new
class of vector-selective insecticides. Antagonists that inhibit the D1-like DARs AaDOP2 and CqDOP2 from the
mosquitoes Aedes aegypti L. and Culex quinquefasciatus Say, respectively, also cause larval mortality in bioassays.
Here, we report on the orthologous DAR, AgDOP2, from the malaria mosquito Anopheles gambiae Giles that was
cloned and pharmacologically characterized in HEK293 cells. Larval bioassays were then conducted to examine the
potential of DAR antagonist insecticides against Anopheles vectors.
Findings: Previous in vitro cAMP accumulation assays demonstrated Gαs coupling for AaDOP2 and CqDOP2 and
dose-dependent inhibition by DAR antagonists. We observed a negligible response of AgDOP2 in the cAMP assay,
which prompted an investigation of alternative coupling for mosquito DARs. In an in vitro IP-One Gαq second
messenger assay of calcium signaling, dopamine stimulation increased IP1 accumulation in AaDOP2-, CqDOP2- and
AgDOP2-expressing cells, and DAR antagonists inhibited IP1 signaling in a dose-dependent manner. In larval
bioassays, DAR antagonists caused considerable mortality of An. gambiae larvae within 24 h post-exposure.
Conclusions: In vitro data reveal pleiotropic coupling of AaDOP2 and CqDOP2 to Gαq and Gαs. In contrast, AgDOP2
appeared to selectively couple to Gαq signaling. In vitro antagonist studies revealed general conservation in
pharmacology between mosquito DARs. In vivo data suggest potential for DAR antagonist insecticides against An.
gambiae. Sequence conservation among the DOP2 receptors from 15 Anopheles species indicates utility of
antagonists to control residual malaria transmission. AgDOP2 Gαq-dependent signaling could be exploited for
An. gambiae control via pathway specific antagonists.
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Background
Control of malaria transmitted by species of Anopheles
mosquitoes is largely achieved via long lasting insecticide
treated nets and indoor residual sprays. New insecticidal
chemistries are needed to protect against mosquitoes
that are resistant to existing insecticides. Further-
more, to achieve malaria eradication or elimination,
new insecticides are required to disrupt outdoor
“residual” transmission by exophilic, day biting mos-
quitoes [1]. Recently, the Innovative Vector Control
Consortium (IVCC; http://www.ivcc.com) issued a
call for three new insecticides with novel modes of
action by 2023 to control malaria mosquitoes [2].
New products must be mosquito-selective and effect-
ive against the many species of Anopheles that
transmit malaria (see [3]).
Fig. 1 In vitro pharmacological characterization of AgDOP2 using IP1 accumulation assay and comparison to AaDOP2, CqDOP2 and hD1.
Cryopreserved cells were plated in 384 well plates (20,000 cells/well), and receptor responses were analyzed for dopamine (upper left panel), or
an EC90 concentration of dopamine in the presence of the indicated antagonists measured as IP1 accumulation. Data were analyzed using
GraphPad prism v.6 software
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Small molecule antagonists of mosquito D1-like dopa-
mine receptors (DARs) show promise as a new class of
insecticides against the mosquito vectors Aedes aegypti
and Culex quinquefasciatus [4–7]. Several antagonists
are potent inhibitors of the Ae. aegypti AaDOP2 and C.
quinquefasciatus CqDOP2 DARs in vitro. These chemis-
tries are >100-fold more selective for the mosquito
DARs versus the human receptor, hD1, and are highly
toxic to mosquito larvae. Further, studies have shown
that invertebrate DOP2 receptors are both phylogen-
etically and pharmacologically distinct from mamma-
lian D1-like receptors [8], a significant rationale for
targeting of these receptors for insecticides.
Here, building on our previous work for AaDOP2 and
CqDOP2, we extend DAR analyses to the Anopheles sys-
tem. The orthologous DAR AgDOP2 was identified from
the genome of Anopheles gambiae, the mosquito vector
of malaria in sub-Saharan Africa, cloned, and pharmaco-
logically characterized. AgDOP2 was expected to exhibit
D1-like pharmacology based on its relation to other in-
vertebrate dopamine receptors. We present molecular
and pharmacological characterization of AgDOP2, as
well as larval bioassays that support the potential for de-
veloping DAR antagonists to control mosquito vectors
of malaria and other devastating human and animal
pathogens.
Findings
Discovery and molecular characterization of DOP2 DARs
from Anopheles species
The AgDOP2 gene [GenBank: KU948225] was identified
from the Anopheles gambiae genome assembly available
at VectorBase (https://www.vectorbase.org/) and manual
annotation was performed as described by [4]. The con-
ceptual AgDOP2 protein sequence was aligned with
AaDOP2 and CqDOP2 using ClustalW [9] (Additional
file 1: Figure S1 and Table S1). Residues required for re-
ceptor activity and associated with the transmembrane
(TM) domains were generally conserved, with greatest
divergence observed in the N-terminal region and the
intracellular loop 3 (IL3). Of note, the IL3, a region
typically associated with coupling to G proteins, is 21
residues longer in An. gambiae as compared to Cx. quin-
quefasciatus and Ae. aegypti. Gene expression of
AgDOP2 in An. gambiae developmental stages and sexes
was confirmed by RT-PCR, suggesting this receptor, like
AaDOP2 and CqDOP2, is constitutively expressed
throughout the mosquito life-cycle, and is likely associ-
ated with essential neurological processes as in other in-
vertebrates [10]. DOP2 sequences from an additional 14
Anopheles species [11] were identified by tBLASTn
searches against the GenBank Whole Genome Shotgun
Contigs (WGS) database and manual annotation. Align-
ments revealed between 78.0 and 99.6 % identity of these
sequences to AgDOP2 (Additional file 1: Figure S2).
In vitro Pharmacology of AgDOP2
For functional characterization, AgDOP2 was synthe-
sized by Genscript (Piscataway, NJ, USA), cloned into
the expression vector pcDNA3.1+ (Invitrogen, Carlsbad,
CA) and a stable cell line expressing the receptor in Hu-
man Embryonic Kidney (HEK)-293 cells was generated
as previously described [4, 6] by plating cells in a 10 cm
dish and transfecting with 15 μl Lipofectamine2000 and
3 μg of plasmid. The pharmacology of AgDOP2 was
evaluated in comparison to that of AaDOP2, CqDOP2
and hD1. On the basis of its relationship to other
invertebrate dopamine receptors [6] (Additional file 1:
Figure S1), AgDOP2 was predicted to couple Gαs, a
guanine nucleotide binding protein that stimulates ade-
nylyl cyclase activity following receptor activation. How-
ever, as the receptor showed no significant response to
dopamine in cAMP accumulation assays (See Additional
file 1: Figure S3), alternative coupling was investigated
using the Cisbio IP-One HTRF accumulation assay
(Cisbio, Bedford, MA, USA) that measures receptor acti-
vation of Gαq and subsequent stimulation of phospho-
lipase C leading to accumulation of downstream inositol
monophosphate (IP1). Assays and analyses were per-
formed as in previous studies for cAMP [5, 6] with the ex-
ception that cryopreserved cells were plated in 1X
Stimulation Buffer (10 mM HEPES; 1 mM CaCl2, 0.5 mM
Table 1 IC50 values (μM± SEM) for inhibition of dopamine-stimulated IP1 response in HEK-293 cell lines by DAR antagonists
Compound AgDOP2 AaDOP2 CqDOP2 Fold selectivity to AgDOP2
AaDOP2 CqDOP2
Amitriptyline 0.23 ± 0.02 0.05 ± 0.003 0.08 ± 0.007 4.4 3.0
Amperozide 18.8 ± 11 5.1 ± 1 2.6 ± 0.6 3.7 7.2
Asenapine 0.0007 ± 0.00008 0.003 ± 0.0005 0.02 ± 0.004 0.3 0.05
Butaclamol 1.2 ± 0.4 1.0 ± 0.2 2.8 ± 0.9 1.2 0.4
Chlorprothixene 0.4 ± 0.007 0.04 ± 0.01 0.01 ± 0.002 0.9 3.2
Methiothepin 0.14 ± 0.008 0.003 ± 0.001 0.01 ± 0.005 4.1 1.1
SCH23390 3.6 ± 0.8 4.7 ± 0.8 8.3 ± 1 0.8 0.4
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MgCl2, 5.5 mM D-Glucose, 4.2 mM KCl, 146 mM NaCl,
50 mM LiCl) and incubated at 37 °C, 5 % CO2, and 90 %
humidity for 2 h. Drugs were diluted to appropriate con-
centration in 1X Stimulation Buffer containing 0.02 % as-
corbic acid, and added to cells to then incubate for 1 h at
37 °C. Ligand stimulation of cells was arrested by addition
of 3 μL/well d2 labelled IP1 and 3 μL/well Cryptate la-
belled anti-IP1 (diluted 1:5 in lysis buffer). Following incu-
bation for 1 h at room temperature, plates were read on
the Synergy 4 (BioTek Instruments, Winooski, VT, USA).
Increases in intracellular IP1 for each receptor were
first measured as concentration response stimulation to
dopamine (Fig. 1; Table 1). EC50 values revealed that
AaDOP2 (1.3 μM± 0.4) and CqDOP2 (0.7 μM± 0.2)
responded robustly to dopamine stimulation while
AgDOP2 (4.7 μM± 0.4) proved 3 and 7 fold less sensi-
tive. These data suggest mosquito receptors can couple
via Gαq in an HEK293 background and reveal a lack of
Gαs-coupling for AgDOP2 in vitro. As expected, no
increase in IP1 accumulation was observed when cells
expressing hD1 were treated with dopamine, demon-
strating that Gαq coupling does not reflect a general
phenomenon for DARs expressed in the in vitro system
employed here. Pleiotropic coupling to Gαs and Gαq has
been reported for a D1-like DAR from the tick, Ixodes
scapularis and the honey bee, Apis mellifera [12, 13].
Similar studies with the Drosophila melanogaster D1-like
receptor, DopR99B, also implicate multiple second
messenger systems [14] and the involvement of Gαq,
Gαi/o- and Gβγ-coupling [15]. While hD1 couples
only via Gαs, other human G protein coupled receptors
(GPCRs) can signal via multiple G proteins [16, 17]. Fur-
ther studies are required to confirm pleiotropic coupling
of mosquito DARs in an insect cell background and in
vivo, as well as to explore potential divergence between
the signaling mechanisms of invertebrate and mam-
malian DARs. Apparent dependence of AgDOP2 on
Gαq-coupling in vitro was an unexpected finding that
may enable the identification of residues determining
G protein interactions and development of products
that selectively disrupt Gαq-mediated signaling of
DOP2 in mosquitoes.
The mosquito DARs exhibited similar profiles in re-
sponse to DAR antagonists (Fig. 1; Table 1), suggesting a
general conservation in receptor pharmacology. A suit-
able signal window was produced for these antagonist
studies by stimulating the receptor-expressing HEK cells
with an EC90 concentration of dopamine (10 μM for
AaDOP2 and CqDOP2 and 100 μM for AgDOP2). Of
the antagonists analyzed, amitriptyline, amperozide,
chlorprothixene and methiothepin showed a higher po-
tency at both AaDOP2 (4–35 fold) and CqDOP2 (3–40
fold), than at AgDOP2. Asenapine followed by SCH23390,
a standard pharmacological probe used in previous
investigations [4–6], proved the most potent for AgDOP2.
Alternatively, butaclamol demonstrated slightly higher
potency for AaDOP2 and AgDOP2, than CqDOP2.
Toxicity of DOP2 antagonists to Anopheles gambiae larvae
As in previous work with Aedes and Culex [5], we ob-
served a correlation between in vitro and in vivo results
in the Anopheles system. The in vivo activity of select
antagonists was tested in L3 An. gambiae larvae, using
Fig. 2 Concentration response curves for An. gambiae showing
percent larval mortality at 24, 48 and 72 h post exposure to
DOP2 antagonists; Each data point represents mean ± SEM
(n ≥ 3 independent experiments)
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concentration response assays conducted at 26 °C as de-
scribed by [6] (note: SCH23390 was not included as this
chemistry had no toxicity to Aedes and Culex larvae).
Larvae of the KISUMU1 strain obtained through the
MR4 (MRA catalog number MRA-762, KISUMU1 F34
strain, established by Dr. G. Davidson, donated by Vin-
cent Corbel) were reared on a 12 h day/night cycle at
75 % RH at 28 °C in 25 × 40 cm plastic pans (400 larvae
per pan) on a diet of ground flake fish food. Antagonists
were selected based on demonstrated toxicity to L3
larvae of Ae. aegypti and C. quinquefasciatus [6]. DAR
antagonists caused mortality of An. gambiae larvae 24 h
post exposure (Fig. 2; Table 2). Methiothepin, asenapine
and chlorprothixene were among the most toxic
compounds at 72 h as compared to amitriptyline
(LC50 = 151 μM), the chemistry employed as positive
control in Ae. aegypti and Cu. quinquefasciatus bio-
assays [4, 5]. Amitriptyline was also identified by
[18] as toxic to An. gambiae larvae and adults.
Methiothepin and chlorprothixene were the most
rapidly toxic to An. gambiae, presumably due to
physico-chemical properties that affect absorption as
discussed by [6]. Asenapine caused negligible toxicity
at 24 h but toxicity was observed by 48 h. Chlor-
prothixene caused mortality (LC50 = 163 μM) ini-
tially, although most survivors remained viable for
several days. The high sequence conservation be-
tween the DOP2 receptors of 14 Anopheles spp.
from sub-Saharan Africa, south-east Asia and Latin
America suggests the DAR antagonists identified
may be broadly active at the DOP2 receptors of mal-
aria vector species, including those that contribute
significantly to residual malaria transmission. Gen-
ome assemblies for multiple Anopheles species [11]
and populations [19] offer the opportunity to expand
comparative molecular and pharmacological studies
of DAR targets across the subfamily Anophelinae.
Conclusions
We present evidence of pleiotropic coupling via Gαs and
Gαq among the mosquito DARs, AaDOP2 and CqDOP2.
In contrast, AgDOP2 appeared to selectively couple to
Gαq signaling in vitro. The heterologous expression
studies also revealed general conservation in pharmacol-
ogy between mosquito DARs including their relatively
similar responses to DAR antagonists. Asenapine was
the most potent and selective AgDOP2 antagonist in
vitro and caused mortality of An. gambiae larvae. This
and other antagonists offer “probes” for further pharma-
cological investigations. While physiochemical properties
such as low lipophilicity and the presence of a charged
amine group at physiological pH may limit the applica-
tion of these chemistries as insecticidal leads, they never
the less offer an important starting point for discovery of
derivatives effective against Anopheles mosquitoes. Se-
quence conservation among the DOP2 DARs of 14
Anopheles species suggests potential to develop products
to control residual transmission of malaria by multiple
vectors. The discovery of an additional signaling path-
way for mosquito DARs may offer opportunities to
disrupt dopaminergic physiology of these vectors with
new chemistries likely active through complex
mechanisms.
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